Payment overview · 2025
General Payments
$633.87
45 reported records · 11 companies
Healthcare provider profile · identity verified
Bryan D Mcdonnell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ARKADELPHIA, AR · NPI 1710996517
Verified facts
What the public records show
CMS Open Payments records show Bryan D Mcdonnell, M.D. received $633.87 in general payments during 2025 across 45 reported records.
Dexcom, Inc. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $155.52 | 24.5% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.86 | 24.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.15 | 13.9% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.03 | 8.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.53 | 7.0% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $38.88 | 6.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.40 | 5.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.04 | 3.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.18 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.28 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.00 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.87 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $155.52 | 13 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $86.86 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $86.86 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $86.86 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.00 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.03 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.33 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.67 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 123 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
164 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 702 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 698 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 695 | 134 |
| Gabapentin | Gabapentin | 444 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 108 |
| Lisinopril | Lisinopril | 435 | 95 |
| Metformin Hcl | Metformin Hcl | 374 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 333 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 64 |
| Simvastatin | Simvastatin | 272 | 56 |
| Sertraline Hcl | Sertraline Hcl | 263 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 258 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 58 |
| Losartan Potassium | Losartan Potassium | 254 | 57 |
| Trazodone Hcl | Trazodone Hcl | 245 | 50 |
| Tramadol Hcl | Tramadol Hcl | 240 | 63 |
| Omeprazole | Omeprazole | 235 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 43 |
| Meloxicam | Meloxicam | 191 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 181 | 45 |
| Atenolol | Atenolol | 176 | 39 |
| Furosemide | Furosemide | 173 | 55 |
| Mounjaro | Tirzepatide | 164 | 19 |
| Alprazolam | Alprazolam | 155 | 31 |
| Valsartan | Valsartan | 152 | 33 |
| Clonazepam | Clonazepam | 144 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 34 |
| Montelukast Sodium | Montelukast Sodium | 141 | 30 |
| Potassium Chloride | Potassium Chloride | 141 | 38 |
| Pregabalin | Pregabalin | 141 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 29 |
| Allopurinol | Allopurinol | 131 | 34 |
| Jardiance | Empagliflozin | 123 | 20 |
| Bupropion Xl | Bupropion Hcl | 120 | 26 |
| Prednisone | Prednisone | 119 | 87 |
| Famotidine | Famotidine | 113 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 25 |
| Eliquis | Apixaban | 112 | 15 |
| Glimepiride | Glimepiride | 109 | 28 |
| Buspirone Hcl | Buspirone Hcl | 108 | 16 |
| Alendronate Sodium | Alendronate Sodium | 106 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 27 |
| Estradiol | Estradiol | 98 | 17 |
| Warfarin Sodium | Warfarin Sodium | 98 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 21 |
| Mirtazapine | Mirtazapine | 95 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 92 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 31 |
| Lorazepam | Lorazepam | 83 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 39 |
| Carvedilol | Carvedilol | 78 | 17 |
| Irbesartan | Irbesartan | 78 | 19 |
| Celecoxib | Celecoxib | 77 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 20 |
| Sucralfate | Sucralfate | 74 | 30 |
| Nortriptyline Hcl | Nortriptyline Hcl | 72 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 15 |
| Spironolactone | Spironolactone | 70 | 16 |
| Cephalexin | Cephalexin | 66 | 52 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 30 |
| Cefdinir | Cefdinir | 62 | 52 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 15 |
| Methocarbamol | Methocarbamol | 60 | 13 |
| Topiramate | Topiramate | 59 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 16 |
| Clonidine Hcl | Clonidine Hcl | 57 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Finasteride | Finasteride | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 12 |
| Baclofen | Baclofen | 52 | suppressed |
| Nabumetone | Nabumetone | 52 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 48 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 48 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 21 |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Colchicine | Colchicine | 36 | suppressed |
| Nystatin | Nystatin | 36 | 24 |
| Ondansetron Odt | Ondansetron | 36 | 16 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 23 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 18 |
| Mupirocin | Mupirocin | 30 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Zaleplon | Zaleplon | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Savella | Milnacipran Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.87 · 45 records | Dexcom, Inc. | ABRYSVO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, NURTEC ODT, PREVNAR 20, UBRELVY, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error